SCHEMBL3012836

SCHEMBL3012836

CCOc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cc(C(F)(F)F)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.41
MAPK1 P28482 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
MAPT P10636 6/20 0.41
RAB9A P51151 5/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
HTT P42858 1/20 0.40
AR P10275 2/20 0.39
PTGS2 P35354 1/20 0.38
NPC1 O15118 4/20 0.38
ATM Q13315 1/20 0.38
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011172 0.91 SMN1; SMN2 (0.52) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3014405 0.89 LMNA (0.43) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3017529 0.89 SMN1; SMN2 (0.48) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3009740 0.89 MAPT (0.48) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008837 0.88 SMN1; SMN2 (0.49) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3006719 0.88 SMN1; SMN2 (0.47) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015732 0.88 LMNA (0.42) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3007437 0.87 CNR2 (0.38) LMNAMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL3016913 0.86 AR (0.52) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3009425 0.86 MEN1 (0.49) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.